1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

28 Jun 2024
Admin
News Article

Agile Therapeutics, Inc. and Insud Pharma, S.L. Sign Definitive Merger Agreement

Overview

Agile Therapeutics, Inc. (“Agile”) (OTCQB: AGRX), a women’s healthcare company, announced a definitive merger agreement with Insud Pharma, S.L. (“Insud”), a global pharmaceutical group based in Spain. Through its US subsidiary Exeltis Project, Inc. (“Exeltis”), Insud will acquire Agile for $1.52 per share in cash, net of assumed liabilities and estimated transaction costs, for an approximate total enterprise value of $45 million.

Words from CEO: Agile Therapeutics

Al Altomari, Agile's Chairperson and CEO, highlighted the company’s achievements, including the approval of Twirla, the only low-dose combined hormonal contraceptive patch, and the development of a commercial platform that spurred Twirla’s growth while managing expenses.
He expressed confidence in Exeltis’ ability to continue building on this progress, viewing the merger as advantageous for both Agile and women's health.

On June 25, 2024, Agile also entered into a cash-out acknowledgment and cancellation agreement with holders of at least 95% of the company’s outstanding common stock warrants, contingent on the merger's completion. Furthermore, Agile amended its Manufacturing and Commercialization Agreement with Corium Innovations, Inc. (“Corium”) to align with the merger terms.

Post Merger

As part of the merger, Insud will provide a line of credit up to $8 million, secured by Agile’s intellectual property.
The initial amount will primarily be used to purchase inventory.
Agile's Board of Directors unanimously approved the transaction, which is expected to close in the third quarter of 2024, subject to stockholder approval and other conditions.
Upon completion, Agile will no longer be publicly listed.

Legal Executives

H.C. Wainwright & Co. acted as Agile’s exclusive financial advisor, and Morgan, Lewis & Bockius LLP served as its legal advisor. Loeb & Loeb LLP and RC Law LLP provided legal counsel to Insud Pharma, S.L. and Exeltis USA, Inc.

About Twirla

Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch for women with a body mass index (BMI) below 30 kg/m². Healthcare providers should note the reduced efficacy in women with a BMI of 25 to 30 kg/m².
Twirla is contraindicated for women with a BMI of 30 kg/m² or higher, and for women over 35 who smoke due to increased cardiovascular risks.
The patch is applied weekly for three weeks, followed by a patch-free week.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!